WHAT THE STUDY ACTUALLY SAYS

Tirzepatide cut BMI by about 18% in adolescents with obesity in a phase 3 trial

In SURMOUNT-ADOLESCENTS, 160 teenagers were randomised to the weekly injection or placebo for 72 weeks. It is a BMI result in a single drug-company-funded trial, not an outcomes study.

Participants achieving at least a 5% BMI reduction at week 72Tirzepatide: 79.6%; Placebo: 28.5%0%40%80%Tirzepatide79.6%Placebo28.5%
Participants achieving at least a 5% BMI reduction at week 72
GroupValue (%)
Tirzepatide79.6
Placebo28.5
Participants achieving at least a 5% BMI reduction at week 72 Proportion of participants in each group reaching the threshold; the placebo arm is the reference [s1]. Source: JAMA

Tirzepatide, the dual-hormone injection already approved to treat obesity in adults, has now been tested in adolescents in a dedicated phase 3 trial. The result, published in JAMA, is large on its own terms: over 72 weeks, the drug was associated with an 18.5% reduction in body mass index, against a 0.5% increase in the placebo group [s1].

What the trial did

SURMOUNT-ADOLESCENTS was a phase 3, randomised, double-blind, 72-week trial run at 31 medical research centres and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the United States, between 16 October 2023 and 2 June 2026 [s1]. It enrolled adolescents aged 12 years to younger than 18 with obesity, or with overweight plus at least one obesity-related complication [s1]. Participants were randomly assigned in a 2:1 ratio to once-weekly subcutaneous tirzepatide, escalated to a maximum tolerated dose of 5, 10 or 15 mg, or to placebo, for 72 weeks, on top of a healthy-lifestyle intervention in both groups [s1]. The trial is registered as NCT06075667 [s2].

The primary endpoint was the percent change in BMI from baseline to week 72 [s1]. A total of 160 participants were randomised — 109 to tirzepatide and 51 to placebo [s1]. Their mean age was 14.6 years, 99 (61.9%) were female, mean body weight was 109.7 kg, and mean BMI was 38.6 [s1].

What it found

At week 72, tirzepatide was associated with an 18.5% reduction in BMI, compared with a 0.5% increase with placebo — an estimated treatment difference of −19.0 percentage points (95% confidence interval −23.9 to −14.1; P<0.001) [s1]. All 10 of the trial's key secondary outcomes were statistically significant in tirzepatide's favour [s1].

The responder analysis gives a feel for how widely that average applied. A BMI reduction of at least 5% was reached by 79.6% of adolescents on tirzepatide, against 28.5% on placebo — a risk difference of 51.2 percentage points (95% CI 36.3 to 66.1; P<0.001) [s1]. The most common adverse events with tirzepatide were gastrointestinal, and mostly mild to moderate [s1].

How to read it

This is a clear, internally consistent efficacy signal in a group where options have been limited, and it should be read as that. It is also a BMI result, not an outcomes result: the trial measured body size over 72 weeks, not whether treated adolescents go on to have fewer heart attacks, less diabetes or better health decades later [s1]. For a drug that would plausibly be taken for years starting in the teens, those longer-term questions are the ones that ultimately matter, and this trial was not built to answer them.

Several limits are worth stating plainly. The trial was modest in size — 160 participants, with only 51 on placebo [s1]. It ran for 72 weeks, which is long for an adolescent drug trial but short against a lifetime of use, and it does not report what happens to weight after the drug is stopped. It was funded by the drug's manufacturer [s1]. And because tirzepatide was given alongside a lifestyle programme, the trial speaks to the drug added to that support, not to the drug alone [s1].

What to watch

The decisions that follow will turn on questions this trial leaves open: whether the BMI reductions are maintained or rebound after treatment ends, how the safety profile reads over years rather than months in a still-growing population, and how regulators and paediatric guideline groups weigh a strong short-term BMI effect against the absence of long-term outcome data. For now, the honest summary is that in one manufacturer-funded phase 3 trial, weekly tirzepatide lowered adolescents' BMI by about 18% more than placebo over 72 weeks [s1].

This article describes clinical-trial results and is not medical advice. Decisions about obesity treatment in adolescents should be made with a clinician.

Sources

  1. Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial — JAMA , November 15, 2026
  2. A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (NCT06075667) — ClinicalTrials.gov

More on

Related coverage